StreetInsider.com News Articles

Phio Pharmaceuticals Announces Participation in Live Virtual Non-Deal Roadshow Series

Tue, 26 May 2026 07:10:58 -0400

Live Presentation and Q&A: Thursday, May 28, 2026 12 PM EDT

King of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL^® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will be followed by a live Q&A session.

"We look forward to participating in the Renmark Virtual Non-Deal Roadshow, where we

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Tue, 26 May 2026 07:00:00 -0400

Live Presentation and Q&A: Thursday, May 28, 2026 12 PM EDT

"We look forward to participating in the Renmark Virtual Non-Deal Roadshow, where

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Tue, 26 May 2026 07:00:00 -0400

Live Presentation and Q&A: Thursday, May 28, 2026 12 PM EDT

"We look forward to participating in the Renmark Virtual Non-Deal Roadshow, where

Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026

Tue, 12 May 2026 07:00:00 -0400

Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attend

Featuring Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman and Force Family Office CEO Steven Saltzstein

King of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Steven Saltzstein, CEO, Force Family Office. Joining them will be Dr. Mary Spellman, Board Certified,

Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026

Tue, 12 May 2026 07:00:00 -0400

Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attend

Featuring Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman and Force Family Office CEO Steven Saltzstein

Phio Pharmaceuticals Corp. (PHIO) Misses Q1 EPS by 34c

Thu, 07 May 2026 18:27:18 -0400

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) reported Q1 EPS of ($0.34).

For earnings history and earnings-related data on Phio Pharmaceuticals Corp. (PHIO) click here.

Form 10-Q Phio Pharmaceuticals For: Mar 31

Thu, 07 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260507/26454061.html

Form 10-Q Phio Pharmaceuticals For: Mar 31

Thu, 07 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260507/26454061.html

Form 8-K Phio Pharmaceuticals For: May 07

Thu, 07 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260507/26453665.html

Form 8-K Phio Pharmaceuticals For: May 07

Thu, 07 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260507/26453665.html

Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

Thu, 07 May 2026 16:05:00 -0400

Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with Favorable Safety and Pathology Data

Key Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply Manufacturing

King of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended March 31, 2026, and provided a business update.

"We are enthusiastic with the successful completion of our Phase 1b clinical trial which now positions us for

Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

Thu, 07 May 2026 16:05:00 -0400

Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with Favorable Safety and Pathology Data

Key Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply Manufacturing

"We are enthusiastic with the successful completion of our Phase 1b clinical trial which now positions us for

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Thu, 23 Apr 2026 07:00:00 -0400

Live Presentation and Q&A: Wednesday, April 29, 2026 12 PM EDT

King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will provide an overview of the Company's INTASYL siRNA platform and discuss recent clinical progress and priorities, followed by a live Q&A.

Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Thu, 23 Apr 2026 07:00:00 -0400

Live Presentation and Q&A: Wednesday, April 29, 2026 12 PM EDT

Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel

Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026

Mon, 13 Apr 2026 07:00:00 -0400

Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual event

R. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert Bitterman, Phio Pharmaceuticals and Steven Saltzstein, Force Family Office

King of Prussia, Pennsylvania--(Newsfile Corp. - April 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Steven Saltzstein, CEO, Force Family Office.

Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026

Mon, 13 Apr 2026 07:00:00 -0400

Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual event

R. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert Bitterman, Phio Pharmaceuticals and Steven Saltzstein, Force Family Office

Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026

Thu, 09 Apr 2026 07:00:00 -0400

Investors and Advisors, and Life Sciences Analysts are Invited to Attend the New York City Event; Virtual Webcast Link Available Below

King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio announced today that Robert Bitterman, Chief Executive Officer and Chairman of the Board, will present at the Centri Capital Conference on Tuesday, April 14, 2026, at Nasdaq Marketsite in New York City. The presentation will also be available via a virtual webcast.

During the session, Mr. Bitterman

Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026

Thu, 09 Apr 2026 07:00:00 -0400

Investors and Advisors, and Life Sciences Analysts are Invited to Attend the New York City Event; Virtual Webcast Link Available Below

During the session, Mr. Bitterman

Form 8-K Phio Pharmaceuticals For: Apr 08

Wed, 08 Apr 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260408/26289514.html

Form 8-K Phio Pharmaceuticals For: Apr 08

Wed, 08 Apr 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260408/26289514.html

Form 424B5 Phio Pharmaceuticals

Wed, 08 Apr 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260408/26289430.html

Form 424B5 Phio Pharmaceuticals

Wed, 08 Apr 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260408/26289430.html

Phio Pharmaceuticals signs manufacturing agreement for cancer drug

Mon, 30 Mar 2026 07:18:26 -0400

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced it has entered into a manufacturing services agreement with a U.S. manufacturer for clinical supply of its lead compound PH-762. The agreement covers both clinical and commercial supply manufacturing for future clinical trials.

The clinical-stage biopharmaceutical company develops therapeutics using its INTASYL gene silencing technology. PH-762 is being evaluated as an intratumoral therapy for cutaneous carcinomas in a Phase 1b trial.

"It is a pleasure to partner with an organization known for its quality and expertise in drug product manufacturing services," said Robert Bitterman, Phio's President and CEO. "Further, we value the strategic advantages of working

Form 8-K Phio Pharmaceuticals For: Mar 30

Mon, 30 Mar 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260330/26237096.html

Form 8-K Phio Pharmaceuticals For: Mar 30

Mon, 30 Mar 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260330/26237096.html